

PROVIDER Update



CONTRACTUAL | NOVEMBER 15, 2022 | UPDATE 22-962 | 5 PAGES

Stay Current with the Injectable Medication HCPCS/DOFR Crosswalk Reference Table – 4th Quarter 2022

Use the updates for dates of service on and after January 23, 2023

On October 11, 2022, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective January 23, 2023, are listed on pages 2-5 of this Provider Update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- 21 new injectable medications to be added to the DOFR crosswalk.
- 28 updates and changes to injectable medication procedure codes.

Additional information

Relevant sections of Health Net's* provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to Health Net's provider website at provider.healthnetcalifornia.com > *Provider Library* under Quick Links, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com within 60 days, by phone or through the Health Net provider website as listed in the right-hand column.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Community Supports (CS) Providers
- Enhanced Care Management (ECM) Providers

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter EPO
 - Ambetter HSP
- Employer Group
 - HMO/POS/HSP
 - EPO
 - PPO
- Medicare Advantage (HMO/PPO) (Wellcare By Health Net)
- Cal MediConnect (Los Angeles/San Diego)
- Medi-Cal
 - Kern
 - Los Angeles
 - Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP
EnhancedCare PPO – 844-463-8188
Health Net Employer Group HMO, POS, HSP, PPO, & EPO – 800-641-7761
Ambetter from Health Net IFP
CommunityCare HMO, PPO, PureCare HSP, & PureCare One EPO – 888-926-2164
Medicare (individual & employer group) (Wellcare By Health Net) – 800-929-9224
Cal MediConnect
Los Angeles County – 855-464-3571
San Diego County – 855-464-3572
Medi-Cal (including CS and ECM providers)
– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

Discover Helpful Tools to Support Your Office

Go to the Provider Library at providerlibrary.healthnetcalifornia.com to quickly access information to help you in your everyday interactions with our Plan. The library includes:

- Provider manuals
- Forms and References
- Education, Training and Other Materials
- Updates and letters
- Contacts
- Health Equity, Cultural and Linguistics Resources

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

New drugs

HCPCS ¹	Drug name	Generic name	Primary category	Secondary category
Q5124	Byooviz™	Ranibizumab-nuna Intravitreal Injection	Therapeutic injection	
J3590	Cimerli™	Ranibizumab-eqrn Intravitreal Injection	Therapeutic injection	
J0717	Cimzia® prefilled syringe kit 200mg NDC 50474-710-81; 50474-710-79	200 mg/ml solution in a single-dose prefilled syringe	Self-injectable	
J0717	Cimzia® vial NDC 50474-700-62	200 mg lyophilized powder in a single-dose vial	Therapeutic injection	
90685	Afluria® peds quadrivalent/ fluzone® quadrivalent	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 ml dosage, for intramuscular use	Therapeutic injection	Immunization
90686	Fluarix® quadrivalent/ flulaval® quadrivalent	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 ml dosage, for intramuscular use	Therapeutic injection	Immunization
90687	Fluzone® quadrivalent	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 ml, for intramuscular use	Therapeutic injection	Immunization
90688	Afluria® quadrivalent / fluzone® quadrivalent	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 ml dosage, for intramuscular use	Therapeutic injection	Immunization
90662	Fluzone® high-dose quadrivalent	Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular	Therapeutic injection	Immunization
90674	Flucelvax® quadrivalent 2022-2023	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 ml dosage, for intramuscular use	Therapeutic injection	Immunization

Additions to injectable medication HCPCS/DOFR crosswalk, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
90682	Flublok® quad injection 2022-23	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	Therapeutic injection	Immunization
90694	Fluad® quadrivalent	Influenza virus vaccine, quadrivalent (aIV4), inactivated, adjuvanted, preservative free, 0.5 ml dosage, for intramuscular use	Therapeutic injection	Immunization
90756	Flucelvax® quadrivalent	Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, antibiotic free, 0.5 ml dosage, for intramuscular use	Therapeutic injection	Immunization
J3590	Fynetra®	Pegfilgrastim-pbbk injection, for subcutaneous use	Self-injectable	Chemotherapy Adjunctive ²
J2426	Invega hafyera™	Paliperidone palmitate injection, 1 mg	Therapeutic injection	
J3490	Nalmefene	Nalmefene hydrochloride injection 1 mg/ml	Therapeutic injection	
C9101	Olinvyk®	Oliceridine injection, for intravenous use	Therapeutic injection	
J3590	Skysona™	Elivaldogene autotemcel IV suspension	Therapeutic injection	
J3590	Spevigo®	Spesolimab-sbzo injection, for intravenous use	Therapeutic injection	
J3590	Xenpozyme™	Olipudase alfa-rpcp for injection, for intravenous use	Therapeutic injection	
J3590	Zynteglo®	Betibeglogene autotemcel	Therapeutic injection	

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J9044	Bortezomib	Bortezomib, 0.1 mg	Generic is added as J9044
J2354	Bynfezia™	Octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	Discontinued

Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
C9094	Enjaymo™	Sutimlimab-jome injection, for Intravenous use	Relaces J3591, C9095
J1435	Estro-5	Estrone per 1 mg	Discontinued
J9395	Fulvestrant	Fulvestrant injection, 25 MG	Generic for Faslodex®- has same HCPCS code as brand
J9331	Fyarro™	Sirolimus protein-bound particles for IV	Replaces J3590
J9212	Infergen®	Interferon alfacon-1	Discontinued
J1655	Innohep®	Tinzaparin sodium, 1000 international units	Discontinued
J2426	Invega sustenna®	Paliperidone palmitate	Replaces J3490
J3490	Invega trinza®	Paliperidone palmitate extended release injectable	Replaces J2426
J3490	Iprivask®	Desirudin Injection 15 mg	Discontinued
Q5109	Ixifi™	Infliximab-qbtX, biosimilar, 10 mg	Has not launch this product
J3490	Kynamro™	Mipomersen sodium	Discontinued
J9274	Kimmtrak®	Tebentafusp-tebn IV solution 100 mcg/0.5m	Replaces C9095
J1932	Lanreotide 1 mg (Cipla)	Lanreotide acetate, 1 mg	New code for the brand by Cipla
J3490	Luveris®	Lutropin alfa for subcutaneous injection 75 unit	Discontinued
J9304	Pemfexy®	Pemetrexed IV solution 500 mg/20 ml	New J-code for brand product
S0148	Peg-intron®	Pegylated interferon alfa-2b, 10 mcg per 0.5 ml (Price is per 10 mcg)	Discontinued
J9247	Pepaxto®	Melphalan flufenamide hydrochloride for IV solution	Discontinued
J9305	Pemetrexed	Pemetrexed disodium for IV solution	Brand Pemfexy® is J9304
S0122	Repronex®	Menotropins 75 international units	Discontinued
J2998	Ryplazim®	Plasminogen, human-tvmh	Replaces J3590

Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
J2777	Vabysmo™	Faricimab-svoa intravitreal injection 6 mg/0.05 ml	Replaces C9097
J9041	Velcade®	Bortezomib, 0.1 mg	Replaces J9044
J9332	Vyvgart™	Efgartigimod alfa-fcab injection, for intravenous use	Replaces J3590
J3299	Xipere™	Triamcinolone acetonide injectable suspension, for suprachoroidal use	Replaces J3490
J7153	Zinbryta®	Daclizumab	Discontinued

¹HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

²If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.